Inclusion Criteria:

1. Have signed an informed consent document indicating that the subjects understands the
purpose of and procedures required for the study and are willing to participate in
the study

2. Written Authorization for Use and Release of Health and Research Study Information
has been obtained

3. Be willing/able to adhere to the prohibitions and restrictions specified in this
protocol

4. Male patients >/= 18 years of age

5. Life expectancy >/= 12 months

6. ECOG Performance Status (PS)
7. Histologically documented diagnosis of adenocarcinoma of the prostate (PCa) with no
histologic variants

8. Prostate cancer recurrence after definitive local therapy (radical prostatectomy
and/or radiation therapy) as evidenced by rising serum PSA, without evidence of
metastases by bone scan or CT scan. a) After radiation: A rising PSA taken to
indicate recurrent prostate cancer in patients with previous definitive external beam
radiotherapy will be defined by the criteria of the American Society for Therapeutic
Radiology and Oncology as (nadir PSA + 2 ng/mL). For patients with prior definitive
brachytherapy, within 2 years of treatment the definition will be (nadir PSA + 3). ,
b) After Radical Prostatectomy: A rising PSA taken to indicate recurrent prostate
cancer in patients with previous radical prostatectomy will be defined by the
criteria of the American Urological Association as any PSA measurement of 0.2, with a
subsequent measurement >0.2 ng/mL

9. Patients who have received androgen ablative therapy for less than 8 weeks
immediately prior to initiation of study drug are eligible provided they had only PSA
evidence of progression (as defined above) with no visible metastases by CT-scan and
bone scan (within 4 weeks) prior to starting androgen ablation

10. Patients must have WBC >/= 3.5 x 10^9/L, ANC >/= 1.5 x 10^9/L, platelets >/= 100 x
10^9/L, Hb >/= 9.0 g/dL); total bilirubin upper limit of normal; serum potassium of >/= 3.5 mEq/L, serum albumin of >/= 3.0
g/dL, creatinine clearance >/= 60 mL/min

11. Patients must have recovered from prior treatment regimens, e.g. surgery, radiation

12. A patient who is sexually active and their partner must agree and use two reliable
barrier forms of contraception (for example, condoms and diaphragm), from first day
of study drug administration until for 1 week after last dose of abiraterone acetate,
unless partner is post-menopausal

13. Able to swallow the study drug whole as a tablet

14. Willing to take abiraterone acetate on an empty stomach; no food should be consumed
at least two hours before and for at least one hour after the dose of abiraterone
acetate is taken

Exclusion Criteria:

1. Patients who have received prior hormonal therapy are excluded from the trial, except
for: patients who have received up to 6 months of hormonal therapy as neoadjuvant
therapy before radical prostatectomy or while on radiation therapy, as long as more
than 1 year has elapsed between discontinuation of the neoadjuvant hormonal therapy
and initiation of hormonal treatment for relapsing disease

2. Any known metastases

3. Prolonged QTc interval on pre-entry electrocardiogram (>/= 450 msec)

4. Clinically significant heart disease as evidenced by myocardial infarction, or
arterial thrombotic events in the past 6 months, severe or unstable angina, or New
York Heart Association (NYHA) Class III-IV heart disease or cardiac ejection fraction
measurement of < 50% at baseline

5. Significant co-morbidity that could affect the safety or evaluability of
participants, including: a) chronically uncontrolled hypertension, defined
conventionally as consistent systolic pressures above 140 or diastolic pressures
above 90 despite therapy. Note that this is NOT a criterion related to particular BP
results at the time of assessment for eligibility, nor does it apply to acute BP
excursions that are related to iatrogenic causes, acute pain or other transient,
reversible causes, b) uncontrolled diabetes mellitus (defined as Hgb A1c > 8.5, or
symptomatic hypoglycemic episodes > 1 per week during the two months prior to
eligibility evaluation, or more than 1 glucose excursion to >300 mg/dL in prior two
months--unless clearly iatrogenic and the cause has been eliminated), c) lung disease
requiring supplemental oxygen, d) known chronic liver disease, or e) known HIV
infection

6. Prior therapy with strontium-89, samarium, rhenium-186 etidronate, anti-angiogenesis
therapy, chemotherapy or androgen biosynthesis inhibitors is not allowed. Previous
immunologic, homeopathic, natural, or alternative medicine therapies are acceptable
provided treatment ended greater than 28 days prior to initiation of study drug

7. Patients who, in the opinion of the investigator, are unable to comply with the
requirements of the study protocol are not eligible

8. Active infection or other medical condition that would make prednisone/prednisolone
(corticosteroid) use contraindicated

9. Active or symptomatic viral hepatitis

10. History of pituitary or adrenal dysfunction

11. Administration of an investigational therapeutic drug within 30 Days of Cycle 1 Day 1

12. Have known allergies, hypersensitivity, or intolerance to abiraterone acetate or
prednisone or their excipients

13. Have a history of gastrointestinal disorders (medical disorders or extensive surgery)
that may interfere with the absorption of the study agents

14. Have a pre-existing condition that warrants long-term corticosteroid use in excess of
study dose